Risk factors

Post-merger Crescent Biopharma is heavily focused on advancing its lead bi-specific antibody CR-001 and ADC programs CR-002 and CR-003. Clinical development and partner dependencies on Paragon Therapeutics dominate the updated risk profile.

Marcum transaction risks now emphasize integrating separate non-attest and attest assets and identifying assumed liabilities.

Federal net operating losses increased to $359.6 million alongside expanded R&D tax credit carryforwards of $18.8 million.

Pending acquisition by Mubadala Capital and TWG Global dominates the risk profile with extensive deal certainty and restriction risks.

Certara faces new risks from FDA disruptions, geopolitical tariffs, and AI market volatility. Foreign currency revenue exposure increased to 31%.

Chord Energy added risks regarding third-party infrastructure dependence and acquisition liabilities. Integration and market risks from the Enerplus arrangement were removed. Geopolitical and ESG risk descriptions were updated.

Competition risk now highlights telehealth, AI, new entrants, direct employer-provider contracting, drug pricing and distribution changes.

NYC vacancies and lease expirations now threaten major commercial rents, including $15.4 million at 250 Livingston Street and $10.3 million at 141 Livingston Street.

Regulatory scrutiny and compliance costs remain central to global operations across US, UK, and EU jurisdictions. Clearing house governance battles and credit risk exposure from daily settlements dominate financial risk. Emerging risks include artificial intelligence adoption, digital asset regulations, and sports event-based contracts litigation.

Macroeconomic and agricultural business cycles dominate the risk profile.

Columbia added risks centered entirely on its Pacific Premier acquisition and key employee retention.

Temperature-controlled warehouses and geographic concentration make downturns, competition, power costs, and property illiquidity especially important.